First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with an autologous stem cell transplant (ASCT), according to data from a Phase 3 trial.
“There is a strong need for additional maintenance treatments for multiple myeloma, where currently approved options are limited,” Meletios Dimopoulos, MD, the trial’s principal investigator, and a professor and chairman of the department of clinical therapeutics at the University of Athens School of Medicine, said in a press release.
“These data could be highly impactful for those who currently have limited options, which is often the case with patients not eligible for a stem cell transplant,” he added.
The results were recently revealed in an oral presentation, “Ixazomib vs placebo as post-induction maintenance therapy in newly diagnosed multiple myeloma (NDMM) patients (pts) Not undergoing autologous stem cell transplant (ASCT): Phase 3 TOURMALINE-MM4 trial,” at the 25th European Hematology Association Annual Congress, held virtually due to the COVID-19 pandemic.
Continue reading this article on Myeloma Research News here.